Abstract: A method of treating infection and/or inflammation in a subject includes steps of providing a polyester biomaterial comprising diol monomers and at least first carboxylate monomers, wherein the first carboxylate monomers are itaconate; and administering the polyester biomaterial to the subject. The polyester biomaterial can be in the form of a biomimetic, and characterized by hydrolytic degradability. The polyester biomaterial may further include second carboxylate monomers. The biomaterial can be poly(itaconate-co-citrate-co-octanediol).

Abstract: The present disclosure provides compositions and methods to increase cellular longevity. In some embodiments, the compositions comprise administering a polynucleotide that encodes transcription factors to a subject in need thereof. In some embodiments, the composition increases telomere length compared to baseline. In some embodiments, the polynucleotide increases anagen hair follicles compared to baseline.

Abstract: Medical compositions and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. More specifically, the medical compositions include a phosphonate-containing polymer. The phosphonate-containing polymers can suppress the expression of various virulence factors without destroying all microbes that may be present.

Abstract: The invention relates to method of treating chronic inflammatory diseases in subjects in need thereof by administering calcium lactate as an active agent. The calcium lactate can be provided in a pharmaceutical, food, or nutrient composition.

Abstract: Injectable compositions that can be added to parenteral nutrition are provided. In particular, a stable injectable composition is provided which includes water, and at least one of about 800 µg to about 4,000 µg of zinc, about 40 µg to about 400 µg of copper, from about 4 µg to about 90 µg of selenium, or from about 1 µg to about 80 µg of manganese per 1 mL of the injectable composition. Methods of preparing and using of the stable injectable composition are also provided.

Abstract: A composition of novel ions, and the use of the composition of novel ions in speeding up the healing process of mammal wounds with a reduction of scarring. In one exemplary embodiment these ions include Rubidium, Calcium, Zinc, and Potassium. These specific ions are referred to as a Protease Down Regulator (PDR).

Abstract: The present invention relates to methods for treating disease, in particular cancer and autoimmune and inflammatory diseases, using engineered cells.

Abstract: The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.

Abstract: The present disclosure provides chimeric antigen receptor polypeptides having antigen recognition domains for CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens, and polynucleotides encoding for the same. The present disclosure also provides for engineered cells expressing the polynucleotide or polypeptides. In some embodiments, the disclosure provides methods for treating diseases associated with CD2, CD3, CD4, CD5, CD7, CD8, and CD52 antigens.

Abstract: The present invention relates generally to the treatment of PML by infusion of activated and expanded autologous lymphocytes.

Abstract: Materials and methods for producing genome-edited cells engineered to express a chimeric antigen receptor (CAR) construct on the cell surface, and materials and methods for genome editing to modulate the expression, function, or activity of one or more immuno-oncology related genes in a cell, and materials and methods for treating a patient using the genome-edited engineered cells.

Abstract: Modified immune cells are provided, the modified immune cells expressing a heterologous polynucleotide comprising a nucleotide sequence encoding a function (e.g., at least one of persistence, proliferation, or cytotoxicity) booster, e.g., an apoptosis inhibitor. In one aspect, the modified T cells further comprise a chimeric antigen receptor. Methods, kits, and components for making and using the modified immune cells are also provided.

Abstract: It is an object to provide a therapeutic composition for treatment of a central nervous disease, a method for producing a therapeutic composition for treatment of a central nervous disease, and a method for producing and preserving a therapeutic formulation for treatment of a central nervous disease. The object is attained by a therapeutic composition for treatment of a central nervous disease, containing synovial membrane-derived mesenchymal stem cells cultured in a serum-free medium.

Abstract: The present disclosure relates to the use of allogeneic populations of mesenchymal stem/stromal cells and related compositions, which populations and compositions comprise cells pooled from multiple donors, in the treatment and/or prevention of COVID-19 infection or for use in the treatment and/or prevention of symptoms associated with COVID-19 infection. The present disclosure also relates to methods for obtaining said compositions.

Abstract: The invention provides compositions for establishing mixed chimerism in a subject. The compositions include CD34+ cells that have been column-purified from an apheresis product and CD3+ cells from an apheresis product that have not been purified through a column. The invention also provides methods of making and using such compositions.

Abstract: Provided herein are methods of using tissue culture plastic-adherent placental adherent cells, e.g. placental stem cells, referred to herein as placental adherent cells, to treat lymphedema and lymphedema-related disorders.

Abstract: Disclosed are enhanced umbilical cord-derived adhesive stem cells, a preparation method therefor, and a use thereof. The enhanced umbilical cord-derived adhesive stem cells have an anti-inflammatory effect, a blood vessel regeneration effect, or a nerve regeneration effect, thereby being usable in a pharmaceutical composition or a cell therapeutic agent for treating or preventing various diseases.

Abstract: Methods of making mixed allergen compositions, e.g., substantially aerobic organism free mixed allergen compositions, and the resulting allergen composition, are provided.

Abstract: Provided herein are methods and pharmaceutical compositions related to the bacteria and microbial extracellular vesicles (mEVs) of Fournierella massiliensis that are useful as therapeutic agents.

Abstract: Provided are compositions comprising a bacterial strain of the genus Bacteroides, for use in a method of increasing the microbiota diversity and/or inducing stability of the microbiota of a subject.

Abstract: A probiotic formulation is provided including one or more bacteria, bacterial strains or bacterial species of the genus Veillonella, genus Faecalibacterium, genus Phascolarctobacteria, genus Oscillospira, genus Ruminococcus, genus Bacteroides, genus Blautia, family Christensenellaceae, genus Dialister, or phylum cyanobacteria.

Abstract: Ammonia oxidizing microorganism preparations for delivery to the gastrointestinal system, kits including ammonia oxidizing preparations for delivery to the gastrointestinal system, and devices for administering ammonia oxidizing preparations to the gastrointestinal system are provided. Methods of introducing ammonia oxidizing microorganisms to the gastrointestinal system are provided. Methods of treating disorders, including gastrointestinal disorders and inflammatory disorders, with ammonia oxidizing microorganism preparations are provided.

Abstract: A composition with Lactobacillus paracasei and a method to treat nasopharyngeal carcinoma through induction of pyroptosis or cell cycle arrest; Lactobacillus paracasei GMNL-653 or heat-killed whole-bacterial liquids thereof are taken as effective ingredients for inhibiting proliferations of nasopharyngeal carcinoma cells or reducing a probability of nasopharyngeal carcinoma development through pyroptosis or cell cycle arrest instead of the mechanism of apoptosis.

Abstract: Abstract: The present invention relates to a Lactobacillus rhamnosus strain. In particular, the present invention relates to a composition comprising a Lactobacillus rhamnosus optionally in combination with a further lactobacilli and the use of the same in the treatment, prevention or alleviation of candidiasis.

Abstract: Disclosed are probiotic compositions including Lactobacillus plantarum, Lactobacillus rhamnosus and Lactobacillus reuteri, as well as methods for the prevention and/or treatment of skin diseases and/or disorders using such compositions.

Abstract: The present disclosure provides a system which enables exogenous probiotics to form a stable microenvironment in a host, can be applied by simple means such as oral administration, can achieve the effect of changing the composition of intestinal microbiota, and eventually plays a positive role in the treatment of malignant tumors.

Abstract: Provided is a lactic acid bacteria composition that is stable under strong acid conditions caused by gastric acid, bile acid, or the like, and specifically, to a lactic acid bacteria composition containing a Lactobacillus paracasei strain and an amino acid as active ingredients. The lactic acid bacteria composition according to the present invention may survive even under strong acidic conditions caused by gastric acid or bile acid and reach the intestine alive, and thus defend against and attack harmful bacteria in the intestine, multiply, produce metabolites, and promote metabolite production, thereby activating the immune system.

Abstract: Described herein is a composition comprising a unique and novel combination of natural ingredients supporting cardiovascular health by contributing to healthy serum cholesterol levels while also reducing CRP and IL-6 cytokine levels. Furthermore, the composition promotes the development of a healthy or healthier gut microbiome. The composition comprises 10%-70% Lactobacillus plantarum, Lactobacillus reuteri and mixtures thereof; 2%-86% plant sterols; and 4%-88% Ashwagandha root powder.

Abstract: Disclosed is an antidepressant composition containing a Pleurotus eryngii extract as an active ingredient, and particularly a food composition and a pharmaceutical composition for preventing, ameliorating, or treating depression containing an extract or fraction of Pleurotus eryngii as an active ingredient. The Pleurotus eryngii extract can inhibit binding between serotonin receptors and selective serotonin reuptake inhibitors by acting on serotonin receptors, can activate signaling mediated by serotonin receptors by acting on serotonin receptors, and can reduce immobility time in a forced swimming test using animal models, and is thus useful in functional foods and pharmaceuticals for preventing, ameliorating, or treating depression.

Abstract: Disclosed are an Inonotus Obliquus dextran, a preparation method and application thereof, and relates to the field of medicines. The dextran has a structural formula as follows: By optimizing the extraction and isolation process, the present disclosure obtains an Inonotus Obliquus dextran, which is structurally determined to be a new polysaccharide. The Inonotus Obliquus dextran prepared by the present disclosure is combined with gemcitabine hydrochloride to inhibit tumor cells with anti-tumor activity against pancreatic cancer, in addition to reduce the dosage of chemotherapeutic drugs as well as the adverse effects of chemotherapeutic drugs.

Abstract: Methods for extracting compounds of interest from a botanical material are disclosed herein. The methods include identifying optimal natural deep eutectic solvents (NaDESs), mixing the identified NaDESs with a botanical material, and isolating compounds of interest from the mixture. Also described are compositions that include the isolated compounds of interest with NaDESs.

Abstract: Nutrient compositions comprising botanical extracts and methods of their use for treating, inter alia, autism or apraxia and/or ameliorating one or more symptoms thereof are disclosed. The use of such compositions for enhancing cognitive function and/or one or more aspects thereof, or for treating stroke or seizures and/or ameliorating one or more symptoms thereof are also disclosed.

Abstract: Compositions may be used in treating or preventing a virus infection in a subject, wherein the virus is from the Coronaviridae family and wherein the composition includes an extract of black currants and/or bilberries. The black currants may be the fruit of Ribes nigrum, and/or the bilberries may be the fruit of Vaccinium myrtillus. The extract may be of the pomaces of the black currants and/or the bilberries.

Abstract: The present invention relates to a composition to help facilitate hair growth while moisturizing the scalp. The composition contains natural and organic ingredients and helps stimulate hair roots to promote growth while relieving itchy and dry skin disorders like alopecia, eczema, and psoriasis. The composition includes olive oil, coconut oil, shea butter, almond, castor oil, grape seed oil, fenugreek oil, aloe vera oil, avocado oil, lavender oil, rosemary oil, tea tree oil, basil, oregano, natural vitamin e, saw palmetto, nettle, horsetail, bhringraj, flax seed, amla, and black seed oil in other embodiments, the composition includes ylang ylang, hemp seed, onion oil, moringa oil, burdock root, andiroba, and honey.

Abstract: Methods and compositions for providing control over a subject's body, include methods and compositions for enhancing the ability of a subject's body to lose weight, or for inducing weight loss in the subject's body. Such methods and compositions may induce thermogenesis in the adipocytes of a subject's body, enhancing the subject's metabolism, inhibit adipogenesis in adipocytes of the individual, and reduce the subject's cravings for food, the subject's appetite and/or the amount of food consumed by the subject. Such a composition may include African mango (Irvinia gabonensis) seed extract, citrus fruits extract from Citrus aurantium, Citrus sinensis, and/or Citrus paradisi (standardized to 5% synephrine and 80% bioflavonoids), Coleus forskholi root extract, and a source of dihydrocapsiate. The composition may be administered with a protein supplement, such as a whey protein supplement (e.g., a hydrolyzed whey protein supplement).

Abstract: Disclosed is a process for removing water soluble extractives from non-woody plants of the genus Hesperaloe, wherein the extract contains at least one saponin. The process includes providing Hesperaloe biomass, milling and washing the biomass with a solvent to yield a crude extract and optionally further purifying and/or concentrating the crude extract. The saponins extracted from Hesperaloe biomass may comprise 25(27)-dehydrofucreastatin, 5(6), 25(27)-disdehydroyuccaloiside C, 5(6)-disdehydroyuccaloiside C, furcreastatin, and yuccaloiside C. An embodiment of present application provides a method of enhancing an immune response to an antigen in a non-human animal comprising administration of a saponin containing Hesperaloe extract. Another embodiment provides an administration of a Hesperaloe-derived immunomodulator containing one or more saponins for the prevention, treatment, and control of one or more conditions in non-human animals.

Abstract: A method for producing a mammalian brain protein hydrolysate composition, by providing a mammalian brain protein hydrolysate, adding Zn ions to the mammalian brain protein hydrolysate to form a complex with the Zn ions and the mammalian brain protein hydrolysate, and obtaining the complex with the Zn ions and the mammalian brain protein hydrolysate in a mammalian brain protein hydrolysate composition. A composition with a mammalian brain protein hydrolysate. A nutritional supplement with a mammalian brain protein hydrolysate. A pharmaceutical composition with a mammalian brain protein hydrolysate.

Abstract: It is an object of the present invention to provide a reversible opening agent for the neural vascular barrier. As a solution, the reversible opening agent for the neural vascular barrier is prepared by including a ligand having an agonistic effect on basigin as an active ingredient. It is preferable that the above ligand contains a polypeptide consisting of an amino acid sequence shown in SEQ ID NO: 1 or the like, or a salt thereof as the active ingredient or the above ligand is cyclophilin A lacking peptidyl-prolyl cis-trans isomerase activity.

Abstract: A method of preventing or treating COVID infection in a subject includes selecting two or more COVED CTL epitopes from a Coronavirus proteome that have a network score that meets a threshold value. An effective amount of a T cell immunogen composition and a pharmaceutically acceptable carrier is administered to the subject. The T cell immunogen composition includes the two or more selected Coronavirus CTL epitopes.

Abstract: Compositions and methods of treating periodontitis are provided. Such compositions and methods typically include a BAR polypeptide and a delivery vehicle.

Abstract: The present invention relates to treatment regimens characterized by high doses of aflibercept (e.g., 8 mg) and extended intervals between doses (e.g., 12 weeks) with improved visual and anatomic outcomes relative to treatment with lower doses such as 2 mg.

Abstract: Disclosed herein are interleukin (IL) conjugates (e.g., IL-2 conjugates) and use in the treatment of one or more indications. Also described herein are pharmaceutical compositions and kits comprising one or more of the interleukin conjugates (e.g., IL-2 conjugates).

Abstract: Described are methods and treatment schedules for treating cancer with intratumoral electroporation of an immunostimulatory cytokine combined with administration of an immune checkpoint inhibitor and a chemotherapeutic agent.

Abstract: The present invention relates to a combination of a CNP agonist and at least one further biologically active moiety or drug for use in a method for the treatment or prevention of disorders that benefit from stimulating growth, pharmaceutical compositions comprising at least one CNP agonist, preferably controlled-release CNP agonist, wherein the pharmaceutical composition comprises at least one further biologically active moiety or drug, to using these pharmaceutical compositions as a medicament, to their use in the treatment of disorders that benefit from stimulating growth and to methods of preventing or treating a patient having a disorder that benefits from stimulating growth.

Abstract: The present invention relates to solid compositions comprising a GLP-1 agonist and a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and their use in medicine.

Abstract: The present invention provides a powder formulation containing glucagon or a glucagon analog for nasal administration, useful in the treatment of hypoglycemia, and in particular the treatment of severe hypoglycemia. The present invention also provides a method of making this powder formulation, and to devices and methods for using the powder formulation.

Abstract: The present invention relates to improved medical therapies for all forms and stages of dementia involving administration of (i) GLP-1 receptor agonists to subjects with metabolic syndrome or (ii) semaglutide.

Abstract: The present invention relates to improved delivery of therapeutic biologics with the molecular weight in the range from 10 kDa to 70 kDa or therapeutic nuclear acids with the molecular weight in the range from 6 kDa to 10 kDa by the concurrent deployment of an insulin-glucose clamp.

Abstract: Disclosed herein is an agent that modulates a cis interaction between Repulsive Guidance Molecule A (RGMa) and Neogenin or lipid rafts. Modulation by the agent may include blocking the cis interaction between RGMa and Neogenin and/or disrupting lipid rafts. In turn, this promotes neuronal cell survival and axon growth and/or regeneration. Also disclosed herein is a method of treating a disease in a subject in need thereof. The method may include administering the agent to the subject. Further disclosed herein is a method of identifying an agent that modulates the cis interaction between RGMa and Neogenin.

Abstract: The present invention relates to the treatment of tissue adhesions, e.g. tissue adhesions that occur after surgical interventions. More specifically, the invention refers to an enzyme having DNAse activity for use in a method of treating or preventing tissue adhesions. The invention also relates to a pharmaceutical composition that comprises an enzyme having DNAse activity for use in a method of treating or preventing tissue adhesions.